Back to top
more

Butterfly Network (BFLY)

(Real Time Quote from BATS)

$0.79 USD

0.79
1,708,379

+0.01 (1.44%)

Updated Apr 29, 2024 09:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging Butterfly Network (BFLY) This Year?

by Zacks Equity Research

Here is how Butterfly Network, Inc. (BFLY) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Butterfly Network, Inc. (BFLY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of -75% and 3.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Butterfly Network, Inc. (BFLY) Upgraded to Buy: Here's Why

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of 17.65% and 6.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axonics (AXNX) delivered earnings and revenue surprises of -25% and 7.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of 15% and 1.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sonendo, Inc. (SONX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sonendo, Inc. (SONX) delivered earnings and revenue surprises of -6.67% and 0.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Butterfly Network (BFLY) Might Surprise This Earnings Season

by Zacks Equity Research

Butterfly Network (BFLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of -61.25% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Butterfly Network, Inc. (BFLY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Butterfly Network (BFLY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Butterfly Network, Inc. (BFLY) and Haemonetics (HAE) have performed compared to their sector so far this year.

iRhythm Technologies (IRTC) Soars 3.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Butterfly Network, Inc. (BFLY) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of 19.05% and 5.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Butterfly Network (BFLY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Butterfly Network, Inc. (BFLY) and Biora Therapeutics, Inc. (BIOR) have performed compared to their sector so far this year.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

New Strong Sell Stocks for April 25th

by Zacks Equity Research

BALY, BFLY, and DNN have been added to the Zacks Rank #5 (Strong Sell) List on April 25, 2022

New Strong Sell Stocks for April 20th

by Zacks Equity Research

BBBY, BALY, and BFLY have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2022.

New Strong Sell Stocks for March 18th

by Zacks Equity Research

BFLY, DAN, and ECPG have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2022

Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

What Makes Butterfly Network, Inc. (BFLY) a New Buy Stock

by Zacks Equity Research

Butterfly Network, Inc. (BFLY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.